MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

53.34 +0.63 (+1.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,358,843
Open 52.93
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 52.71
Today's Range 52.83 - 53.54
52wk Range 37.51 - 60.85
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
From Genentech
Via Business Wire
News headline image
3 International ETFs for Investors Looking Beyond U.S. Stocks ↗
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%. 
Via The Motley Fool
Topics Artificial Intelligence ETFs

Performance

YTD
+3.7%
+3.7%
1 Month
+2.9%
+2.9%
3 Month
-11.1%
-11.1%
6 Month
+12.1%
+12.1%
1 Year
+34.5%
+34.5%

More News

Read More
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
Via The Motley Fool
News headline image
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
From Genentech
Via Business Wire
News headline image
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
From Genentech
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
Via Investor Brand Network
Topics Intellectual Property
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
From BioMedWire
Via GlobeNewswire
News headline image
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
From Genentech
Via Business Wire
News headline image
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
From Genentech
Via Business Wire
News headline image
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
From Genentech
Via Business Wire
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
Via The Motley Fool
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
Via MarketMinute
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
Via MarketMinute
Topics Economy World Trade
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
Via MarketMinute
Topics Intellectual Property
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
Via Finterra
Topics Economy Intellectual Property World Trade
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
Via MarketMinute
Topics Intellectual Property
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
Via MarketMinute
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
Via MarketMinute
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Via Finterra
Topics Economy Intellectual Property
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
Via MarketMinute
Topics Intellectual Property
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
Via MarketMinute

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 53.34
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 05/22/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story